ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Hensing Discusses Studies in Stage III NSCLC

Thomas A. Hensing, MD
Published: Friday, Oct 06, 2017



Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non–small cell lung cancer (NSCLC).

Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.

The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
 


Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non–small cell lung cancer (NSCLC).

Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.

The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x